The oral version was previously available for diabetes management (under the brand name Rybelsus), but this new FDA approval specifically authorizes a high-dose oral formulation for chronic weight management
Early, in-depth review article that evaluates the similarities and differences between short-acting and long-acting GLP-1R agonists in terms of glucose-lowering efficacy and adverse effects, and discusses the possibilities for utilizing these agents for individualized treatment of T2DM
[59] Tirzepatide is sold under the brand names Mounjaro [9] and Zepbound
These medications are designed to act on pathways associated with the GLP-1 hormone, which is naturally released in the gastrointestinal tract after eating
Often used in mechanistic endocrine research to compare GHRH-pathway signaling vs
Dulaglutide, albiglutide, and semaglutide have half-lives that range from 4.7 to 5.5, 5.76.8, and 5.76.7 days, respectively [72]